This was confirmed by our findings that Dap treatment decreased renal SGK1 protein expression, reduced circulating IL‐17 levels, increased circulating IL‐10 levels, and significantly attenuated the pathological kidney changes in DM mice, all of which were not observed in mice treated with Vog. This evidence concerns the gene IL17A and diabetes mellitus.